GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

GenScript continues to build on its fast and dependable in vitro transcription RNA synthesis service, offering a new self-amplifying RNA format that enhances the potency and efficacy of vaccines, immunotherapies, and gene therapies

PISCATAWAY, N.J., May 13, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life science research tools and services, has today announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA). This cutting-edge addition reinforces GenScript's position at the forefront of IVT RNA technology, offering a new and novel format for researchers working in applications such as vaccine, cancer immunotherapy, and gene or cell therapy development.

GenScript Self-Amplifying RNA